CASI Pharmaceuticals, Inc. (CASI) financial statements (2020 and earlier)

Company profile

Business Address 9620 MEDICAL CENTER DR
ROCKVILLE, MD 20850
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5485432751115
Cash and cash equivalents5484432751115
Short-term investments11     
Receivables1    0(0)
Inventory, net of allowances, customer advances and progress billings50    
Inventory50     
Other undisclosed current assets1700000
Total current assets:6293442761115
Noncurrent Assets
Operating lease, right-of-use asset9
Property, plant and equipment1210000
Long-term investments and receivables14      
Long-term investments14      
Intangible assets, net (including goodwill)1719    
Intangible assets, net (excluding goodwill)1719     
Other noncurrent assets1000000
Total noncurrent assets:412110000
TOTAL ASSETS:103113452861116
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8231111
Accounts payable5121110
Accrued liabilities3110000
Debt 1     
Due to related parties  2    
Deferred revenue and credits   00
Other undisclosed current liabilities     (0)(0)
Total current liabilities:8451111
Noncurrent Liabilities
Long-term debt and lease obligation  1111 
Long-term debt, excluding current maturities  1111 
Liabilities, other than long-term debt10 499 
Other liabilities10     
Derivative instruments and hedges, liabilities   499 
Total noncurrent liabilities:10161111 
Total liabilities:947712121
Temporary equity, carrying amount21      
Stockholders' equity
Stockholders' equity attributable to parent, including:731093921(6)(0)15
Common stock1111000
Treasury stock, value(8)(8)(8)(8)(8)(8)(8)
Additional paid in capital607597499470434433422
Accumulated other comprehensive loss(3)(1)     
Accumulated deficit(524)(479)(453)(442)(432)(425)(399)
Warrants and rights outstanding     98
Other undisclosed stockholders' equity attributable to parent     (9)(8)
Total stockholders' equity:731093921(6)(0)15
TOTAL LIABILITIES AND EQUITY:103113452861116

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues4   00 
Revenue, net  00 
Cost of revenue(9)(0)  (0)(20) 
Cost of goods and services sold(4)   (0)(0) 
Gross profit:(4)(0)  0(20) 
Operating expenses(43)(27)(11)(9)(7)(7)(6)
Operating loss:(47)(27)(11)(9)(7)(26)(6)
Nonoperating income1      
Foreign currency transaction gain, before tax1      
Interest and debt expense(0)(0)     
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes1(0)0    
Loss from continuing operations before equity method investments, income taxes:(45)(27)(11)(9)(7)(26)(6)
Other undisclosed loss from continuing operations before income taxes     (0) 
Net loss:(45)(27)(11)(9)(7)(26)(6)
Net income attributable to noncontrolling interest0      
Other undisclosed net income (loss) attributable to parent(1)  (0)(0) 0
Net loss available to common stockholders, diluted:(46)(27)(11)(9)(7)(26)(6)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(45)(27)(11)(9)(7)(26)(6)
Other undisclosed comprehensive loss(2)      
Comprehensive loss:(47)(27)(11)(9)(7)(26)(6)
Comprehensive income, net of tax, attributable to noncontrolling interest0      
Other undisclosed comprehensive loss, net of tax, attributable to parent (1)     
Comprehensive loss, net of tax, attributable to parent:(46)(29)(11)(9)(7)(26)(6)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: